A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

本研究旨在确定CDX-1140（CD40抗体）单药或联合CDX-301（FLT3L）、帕博利珠单抗或化疗的最大耐受剂量（maximum tolerated dose, MTD），并在确定该最大耐受剂量后，于扩展队列中进一步评估其耐受性与疗效。